EMEA-001251-PIP01-11-M03

Key facts

Invented name
Imlygic
Active substance
talimogene laherparepvec
Therapeutic area
Oncology
Decision number
P/0087/2017
PIP number
EMEA-001251-PIP01-11-M03
Pharmaceutical form(s)
Solution for injection
Condition(s) / indication(s)
Treatment of solid malignant non-central-nervous-system tumours
Route(s) of administration
Intratumoral use
Contact for public enquiries
Amgen Europe B.V.
United Kingdom
E-mail: pipenquiry@amgen.com
Tel. +44 (0)1223 420305
Decision type
PM: decision on the application for modification of an agreed PIP

Decision

How useful was this page?

Add your rating